Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/215286
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNavero Rodríguez, José Manuel-
dc.contributor.authorBoldú Roig, Júlia-
dc.contributor.authorPinilla, Laura-
dc.contributor.authorVidal Martí, María-
dc.contributor.authorAntón, Alfonso-
dc.date.accessioned2024-09-19T10:07:24Z-
dc.date.available2024-09-19T10:07:24Z-
dc.date.issued2024-07-30-
dc.identifier.issn2077-0383-
dc.identifier.urihttps://hdl.handle.net/2445/215286-
dc.description.abstractIntroduction: To compare the efficacy and safety of trabeculectomy with a collagen matrix implant (Ologen (R)) versus trabeculectomy with mitomycin C (MMC) versus trabeculectomy with both Ologen (R) and MMC (OLO + MMC). Methods: This non-randomized study included 119 eyes of 101 patients with uncontrolled open-angle glaucoma who underwent trabeculectomy, either alone or combined with phacoemulsification. The data were initially recorded following a standard surgical protocol, using an electronic database with structured fields. The patients were divided into three groups: 44 received trabeculectomy with adjunctive MMC (MMC group), 34 received surgery with Ologen (R) (OLO group), and 41 received surgery with both Ologen (R) and MMC (OLO + MMC group). The main outcome measures were the change in intraocular pressure (IOP), change in number of medications needed, complete success rate (defined as IOP <= 20 mmHg and at least 20% IOP reduction without hypotensive medications), rate of complications, and rate of postoperative interventions. The follow-up period was 36 months. Results: IOPs significantly decreased (p = 0.01) in all groups across all study visits, decreasing from 19.8 +/- 4.6 mmHg to 12.7 +/- 4.2 mmHg in the MMC group, from 20.5 +/- 4.7 mmHg to 13.9 +/- 3.5 mmHg in the OLO group, and from 23.5 +/- 6.1 mmHg to 13.1 +/- 3.5 mmHg in the OLO + MMC group. After correcting for the baseline IOP, only the first two postoperative visits (first week and first month) showed a significantly greater IOP reduction in the OLO + MMC group. The number of hypotensive medications was significantly reduced from 3.1 +/- 0.6 to 0.56 +/- 1.1 in the MMC group, from 2.9 +/- 0.4 to 0.83 +/- 1.1 in the OLO group, and from 3.0 +/- 0.6 to 0.45 +/- 0.95 in OLO + MMC group, with no statistically significant differences among the groups (p = 0.57). The complete success rates were 63.6% in the MMC group, 67.6% in the OLO group, and 80.5% in the OLO +MMC group, with no statistically significant differences between the groups (p = 0.21). Suture release was significantly more frequent in the MMC group (86.1%) than in the OLO group (62.1%) and in the OLO + MMC group (45.9%; p = 0.02). Bleb needling, with (33.3%; p = 0.005) or without (66.7%; p = 0.0001) 5-fluorouracil injection (5-FU), was significantly more common in the MMC group. The highest complete success rate (61%) was observed in the OLO + MMC group. Conclusions: The use of Ologen (R) and mitomycin C provided similar surgical IOP reduction in glaucoma surgery compared with either MMC or Ologen (R) alone, but significantly reduced the need for postoperative interventions.-
dc.format.extent13 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI AG-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm13154463-
dc.relation.ispartofJournal of Clinical Medicine, 2024, vol. 13, num. 15-
dc.relation.urihttps://doi.org/10.3390/jcm13154463-
dc.rightscc by (c) Navero Rodríguez, José Manuel et al, 2024-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationGlaucoma-
dc.subject.classificationCol·lagen-
dc.subject.classificationCirurgia ocular-
dc.subject.otherGlaucoma-
dc.subject.otherCollagen-
dc.subject.otherEye surgery-
dc.titleClinical Impact of the Use of Ologen in Filtering Surgery Performed in Uncontrolled Glaucoma-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2024-09-17T15:08:02Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid39124730-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
jcm-13-04463.pdf1.63 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons